Peripheral Neuropathy Trial, Recruiting NCT06420141 Sponsor: Indiana University Condition: Peripheral Neuropathy
Back to Peripheral Neuropathy

Peripheral Neuropathy Trial, Recruiting

NCT06420141
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Fracture Group:

  • People between 18 and 85 years old
  • People who have a single ankle fracture (of a specific type, known as AO/OTA types A–C) that is being treated with surgery
  • People whose other injuries (outside of the broken ankle) are considered minor in severity
  • People who can speak, read, and understand English

Control Group (no fracture):

  • People between 18 and 85 years old
  • People who can speak, read, and understand English

Who may not be able to join:

Fracture Group:

  • People who were already being treated for a long-term (chronic) pain condition before the ankle injury
  • People who are on a formal pain management agreement (sometimes called a "pain contract")
  • People whose fracture was caused by an underlying disease (such as cancer), rather than an injury
  • People who were taking gabapentin (a nerve pain medication) or opioid pain medications every day before joining the trial

Control Group:

  • People who have ongoing long-term (chronic) pain or a current short-term (acute) pain condition
  • People who have ever had a bone fracture
  • People who are currently taking any pain medications
  • People who have had any previous orthopaedic (bone or joint) surgery
  • People who have had any surgery within the last 5 years
  • People who have nerve damage in their hands or feet (peripheral neuropathy)
  • People who have had a major surgery, or have a serious medical condition such as heart disease, metabolic disorders, kidney disease, neurological disorders, or severe psychiatric conditions — as determined by the lead researcher

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Roman Natoli, MD, PhD, Indiana University

Phone: 317-274-5264

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
3 January 2024
Est. completion
31 March 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Chronic Pain Grading Scale; Douleur Neuropathique (Neuropathic Pain) 4; Assessment of Chronic Regional Pain Syndrome (CRPS); Central Sensitization measure; Pain Inhibitory Test

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov